PHAXIAM Therapeutics S.A. (PHXM.PA)
EUR 1.73
(-0.57%)
EUR 1.73
(-0.57%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -23.48 Million EUR | -10201.75% |
| 2022 | -228 Thousand EUR | 99.58% |
| 2021 | -53.79 Million EUR | 26.61% |
| 2020 | -73.3 Million EUR | -16.98% |
| 2019 | -62.65 Million EUR | -63.93% |
| 2018 | -38.22 Million EUR | -14.0% |
| 2017 | -33.53 Million EUR | -52.33% |
| 2016 | -22.01 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -5.31 Million EUR | 0.0% |
| 2024 Q1 | -5.31 Million EUR | 4.99% |
| 2023 Q3 | -5.69 Million EUR | 53.36% |
| 2023 Q1 | -6.1 Million EUR | -866.39% |
| 2023 FY | -23.48 Million EUR | -10201.75% |
| 2023 Q4 | -5.59 Million EUR | 1.63% |
| 2023 Q2 | -12.2 Million EUR | -100.0% |
| 2022 Q2 | -1.02 Million EUR | 0.0% |
| 2022 Q4 | 796 Thousand EUR | 115.49% |
| 2022 Q3 | -5.13 Million EUR | -401.86% |
| 2022 FY | -228 Thousand EUR | 99.58% |
| 2021 Q2 | -27.95 Million EUR | 0.0% |
| 2021 Q4 | -25.84 Million EUR | 0.0% |
| 2021 FY | -53.79 Million EUR | 26.61% |
| 2020 Q4 | -38.33 Million EUR | 0.0% |
| 2020 FY | -73.3 Million EUR | -16.98% |
| 2020 Q2 | -34.96 Million EUR | 0.0% |
| 2019 Q4 | -33.37 Million EUR | 0.0% |
| 2019 FY | -62.65 Million EUR | -63.93% |
| 2018 FY | -38.22 Million EUR | -14.0% |
| 2017 FY | -33.53 Million EUR | -52.33% |
| 2016 FY | -22.01 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Nicox S.A. | -20.88 Million EUR | -12.485% |
| European Medical Solutions | -709 Thousand EUR | -3212.835% |
| FERMENTALG | -14.14 Million EUR | -66.016% |